• In early March 2026, Bristol Myers Squibb reported positive interim Phase 3 SUCCESSOR-2 results for oral mezigdomide in relapsed or refractory multiple myeloma and secured U.S. FDA approval for Sotyktu (deucravacitinib) to treat adults with active psoriatic arthritis, expanding its presence in hematology and immunology.
• Together, these developments highlight Bristol Myers Squibb’s depth in targeted protein degradation and TYK2 inhibition, underscoring how its research platforms can translate into new treatment options across oncology and immune-mediated diseases.
• We’ll now examine how the SUCCESSOR-2 mezigdomide data could influence Bristol Myers Squibb’s 2026 investment narrative and longer-term risk balance.

AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Bristol-Myers Squibb Investment Narrative Recap

To own Bristol Myers Squibb, you need to believe its newer oncology and immunology platforms can gradually offset pressure from aging blockbusters and pricing reform. The SUCCESSOR-2 mezigdomide data and Sotyktu’s new psoriatic arthritis approval support that thesis by adding clinical depth in multiple myeloma and immune disease, but they do not remove the near term overhang from patent cliffs and high debt, which remain central to the risk profile.

Among recent announcements, the FDA’s acceptance of the iberdomide NDA for relapsed or refractory multiple myeloma looks particularly relevant. Together with mezigdomide, it reinforces Bristol Myers Squibb’s attempt to refresh its multiple myeloma franchise ahead of generic competition, creating a cluster of potential hematology catalysts that could matter more as older therapies lose exclusivity.

Yet, even if these late stage wins keep coming, investors should still be aware of the strain that high debt and rising interest costs could...

Bristol-Myers Squibb's narrative projects $41.3 billion revenue and $9.2 billion earnings by 2028. This requires a 4.7% yearly revenue decline and a $4.2 billion earnings increase from $5.0 billion today.

Uncover how Bristol-Myers Squibb's forecasts yield a $59.91 fair value, in line with its current price.

Exploring Other Perspectives

Some of the lowest priced analysts were assuming revenues would shrink about 6.4 percent a year to roughly US$39.2 billion, even as mezigdomide and other readouts tested that cautious view, so if you are following the pipeline risk you may find their much more pessimistic stance useful as a reference point alongside more optimistic takes.

Explore 11 other fair value estimates on Bristol-Myers Squibb - why the stock might be worth 20% less than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Bristol-Myers Squibb research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Bristol-Myers Squibb research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bristol-Myers Squibb's overall financial health at a glance.

Interested In Other Possibilities?

Our top stock finds are flying under the radar-for now. Get in early:

• Invest in the nuclear renaissance through our list of 86 elite nuclear energy infrastructure plays powering the global AI revolution.
• Uncover the next big thing with 28 elite penny stocks that balance risk and reward.
• Find 48 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.